Articles

A GLP-grade non-replicative Leishmania major parasite protects hamsters from lethal leishmaniasis infection, setting the stage for human clinical trials and the first potential vaccine for leishmaniasis.

Scientists combined engineered E. coli with artificial intelligence to produce effective, high-quality protein and antibody-based drugs at a large scale.

Scientists found evidence of telomeres in the 1930s, but did not identify them until the 1970s. Since then, researchers’ understanding of telomeres and their role in DNA repair, aging, and disease has expanded exponentially.

Researchers employ CRISPR technology in a variety of creative ways to control the spread of vector-borne illnesses.

Respiratory viruses are the most common cause of asthma attacks, but COVID-19 does not send asthma patients to the hospital more often than others. Some researchers suspect that having asthma may actually protect patients from severe COVID-19.

Transplanted astrocyte precursor cells promote healing in mouse brains after white matter strokes.

Through research experience, scientists develop a strong sense of resiliency. The COVID-19 pandemic put that resiliency to the test, and now as vaccination rates increase and communities begin to open up, it’s time to take a breath.

A biopharmaceutical company established a new method for isolating and editing hematopoietic stem cells from patients to provide stem cell therapies for diseases such as sickle cell disease.

Researchers use machine learning to identify generic drugs that are promising candidates for affordable and accessible cancer treatments.

Art therapy improved brain connectivity in patients with Parkinson’s disease, suggesting that creating art may help treat it and other neurodegenerative diseases.